{"product_id":"coll-ansoff-analysis","title":"(COLL) Collegium Pharmaceutical, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Growth Strategy Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Collegium Pharmaceutical, Inc. Ansoff Matrix Analysis maps growth options across market penetration, market development, product development, and diversification to show strategic paths and priorities; the page includes a real preview\/sample so you can judge style and depth before buying. Purchase the full version to receive the complete, ready-to-use company-specific analysis for research, strategy, or investment use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXtampza ER formulary defense\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXtampza ER is Collegium Pharmaceutical, Inc.'s abuse-deterrent oxycodone for severe, persistent pain, and market penetration means protecting share in existing U.S. pain accounts. The key is steady payer access and prescriber retention, because formulary loss can quickly cut scripts and refill volume. In 2025, this is a defense game: keep the brand preferred, keep it covered, and stop erosion in established accounts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNucynta franchise retention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical, Inc. keeps Nucynta Franchise Retention strong by pairing Nucynta ER and Nucynta IR, giving it 2 tapentadol options in one franchise. That helps defend share with chronic and acute pain prescribers already using tapentadol, so the brand stays embedded in the same treatment pathway. The 2-product setup also reduces switching risk and supports repeat prescribing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBelbuca share growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBELBUCA adds buprenorphine buccal film to Collegium Pharmaceutical, Inc.'s pain mix, so market penetration means deeper use among clinicians treating 24\/7 chronic pain. It grows branded-opioid share inside the same U.S. patient pool by giving prescribers another option for ongoing pain management.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSymproic add-on prescribing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSymproic (naldemedine) extends Collegium Pharmaceutical, Inc.’s reach inside the same opioid-treated patient base as its pain brands, so prescribers can add it when opioid-induced constipation appears. That matters because OIC affects about 40% to 80% of chronic opioid users, which supports repeat prescribing and tighter portfolio stickiness.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame patient base\u003c\/li\u003e\n\u003cli\u003eRepeat add-on use\u003c\/li\u003e\n\u003cli\u003eSupports portfolio stickiness\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eU.S. specialty-prescriber focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollegium Pharmaceutical, Inc. is a U.S.-only specialty pharma company, so market penetration means going deeper with pain specialists and other opioid-prescribing clinicians, not entering new geographies. The clearest share-growth lever is heavier call coverage and tighter account focus in the same prescribing base.\u003c\/p\u003e\n\u003cp\u003eThat fits a depth-over-breadth play: more scripts per account, better retention, and stronger access in the core pain channel. In Ansoff terms, this is classic market penetration, where growth comes from existing products and existing U.S. prescribers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eU.S. focus limits geographic expansion.\u003c\/li\u003e\n\u003cli\u003ePain specialists drive the key share gains.\u003c\/li\u003e\n\u003cli\u003eGrowth depends on account depth.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium’s U.S. Pain Portfolio Drives Repeat Scripts and Share Defense\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical, Inc.'s market penetration is a U.S. share-defense play: keep Xtampza ER, Nucynta, BELBUCA, and Symproic inside the same pain-prescribing base. Growth comes from more scripts per account, strong payer access, and lower switching, not new geographies. OIC affects 40% to 80% of chronic opioid users, so add-on use supports repeat prescribing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003ePenetration effect\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eXtampza ER\u003c\/td\u003e\n\u003ctd\u003eProtects U.S. share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNucynta\u003c\/td\u003e\n\u003ctd\u003eRetains tapentadol users\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBELBUCA\u003c\/td\u003e\n\u003ctd\u003eDeepens chronic-pain use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSymproic\u003c\/td\u003e\n\u003ctd\u003eAdds OIC follow-on scripts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix framework for analyzing Collegium Pharmaceutical, Inc.’s growth strategy across existing and new products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise Collegium Pharmaceutical Ansoff Matrix to quickly clarify growth options and ease strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary regulatory filings, investor presentations, clinical studies, and financial reports to validate Ansoff Matrix growth paths for Collegium Pharmaceutical, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNucynta IR acute-pain segment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNucynta IR is tapentadol immediate-release, sold in 50 mg, 75 mg, and 100 mg tablets, so it can serve short-term acute pain as well as chronic pain use. This is market development in Ansoff terms: the same product is pushed into a new patient segment, expanding Collegium Pharmaceutical, Inc. beyond its core long-term pain base. Acute pain is a large, high-turnover setting, so even modest share gains can add meaningful refill and new-start volume.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXtampza ER post-acute settings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXtampza ER is approved for severe, persistent pain needing daily, continuous, long-term opioid therapy, so moving it into post-acute and continuing-care settings extends the same brand beyond hospital use. That is market development: Collegium Pharmaceutical, Inc. is widening where the product is prescribed, especially after discharge, in rehab, and in long-term care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBelbuca chronic-pain clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBelbuca is positioned for patients who need around-the-clock opioid analgesia, so moving deeper into chronic-pain clinics and specialist channels widens prescribing without changing the product. This is market development in Ansoff terms: same brand, more sites of care, more eligible patients. Collegium Pharmaceutical, Inc. can grow Belbuca by reaching pain physicians and clinic networks that already treat persistent pain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSymproic opioid-induced constipation base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSymproic treats opioid-induced constipation in adults, so it extends Collegium Pharmaceutical, Inc. beyond pain control into supportive care. With constipation affecting roughly 40% to 80% of patients on opioids, the base expands as more treated patients keep long-term opioid use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets adults with opioid-induced constipation\u003c\/li\u003e\n\u003cli\u003eBroadens use across opioid-treated patients\u003c\/li\u003e\n\u003cli\u003eAdds supportive care beyond pain relief\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat makes Symproic a market development play: deeper penetration in the same patient pool without changing the core product need. In 2025, its role stayed tied to chronic opioid users, where persistence and repeat use matter most.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBroader U.S. payer access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBroader U.S. payer access is a clean market-development move for Collegium Pharmaceutical, Inc.: the products stay in the same U.S. market, but more commercial and government plans can widen coverage. Because Collegium’s 2024 net product sales topped $680 million, even small gains in formulary access can lift prescription volume fast.\u003c\/p\u003e\n\u003cp\u003eWith most U.S. drug spend routed through payer and pharmacy channels, access wins matter more than geography. Extending coverage for existing brands can add patients without a new launch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame geography, wider customer base\u003c\/li\u003e\n\u003cli\u003eMore formulary wins can boost scripts\u003c\/li\u003e\n\u003cli\u003eAccess gaps still limit brand growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium Expands Existing Brands Into New Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical, Inc. is using market development by pushing existing brands into new patient and care settings, not changing the drugs. In 2025, Symproic stayed tied to chronic opioid users, and broader payer access could lift scripts across the same U.S. market.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003e2025\/2024 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product sales\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$680M in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowth lever\u003c\/td\u003e\n\u003ctd\u003eFormulary access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUse case\u003c\/td\u003e\n\u003ctd\u003eSame brands, new patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eCollegium Pharmaceutical, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality, applied to Collegium Pharmaceutical’s growth options across market penetration, product development, market development, and diversification.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXtampza ER abuse-deterrent design\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXtampza ER is Collegium Pharmaceutical, Inc.'s abuse-deterrent, extended-release oxycodone, so it fits product development: the Company Name is improving the drug design, not entering a new pain segment. It gives prescribers a branded alternative to conventional oxycodone ER, and Company Name's pain portfolio has continued to drive more than $600 million in annual net sales in recent recent reporting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNucynta ER extended-release tapentadol\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNucynta ER (extended-release tapentadol) adds a long-acting opioid option for chronic pain, so Collegium Pharmaceutical, Inc. broadens its pain portfolio without leaving its core market. The ER form gives the company a distinct dosage type for patients who need around-the-clock pain control.\u003c\/p\u003e\n\u003cp\u003eIn Ansoff Matrix terms, this is product development: a new format built for the same pain segment, not a move into a new market. It strengthens the lineup around tapentadol while keeping the commercial focus on chronic pain treatment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNucynta IR immediate-release tapentadol\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNucynta IR is the immediate-release tapentadol form, adding a second dosage form to Collegium Pharmaceutical, Inc.'s franchise. It targets acute pain inside the same therapeutic area, so this is product development in the Ansoff Matrix, not a new market move. The two-form strategy helps the Company cover both chronic and acute pain needs with one molecule.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBelbuca buprenorphine buccal film\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBelbuca, a buprenorphine buccal film, expands Collegium Pharmaceutical, Inc.'s pain portfolio with a branded option for chronic pain patients needing opioid analgesia. It is a clear product-line expansion because it adds a different dosage form and route of delivery to the Company Name's existing offerings.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBranded buprenorphine buccal film\u003c\/li\u003e\n\u003cli\u003eTargets chronic pain opioid users\u003c\/li\u003e\n\u003cli\u003eExpands the pain product line\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSymproic naldemedine 0.2 mg\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSymproic, naldemedine 0.2 mg, adds a once-daily opioid-induced constipation option to Collegium Pharmaceutical, Inc.’s portfolio. It fits the same opioid care ecosystem as Collegium Pharmaceutical, Inc.’s pain brands, so it supports product development by deepening the stack around one patient group. OIC affects about 40% to 80% of chronic opioid users, so the cross-sell fit is clear.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e0.2 mg naldemedine dose\u003c\/li\u003e\n\u003cli\u003eTargets opioid-induced constipation\u003c\/li\u003e\n\u003cli\u003eSupports the same pain-care niche\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium Expands Its Pain Franchise Through Product Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical, Inc. is using product development by extending its pain franchise with new dosage forms and delivery routes, not by entering a new market. Xtampza ER, Nucynta ER, Nucynta IR, Belbuca, and Symproic all deepen the same opioid-care niche, and the pain portfolio has generated more than $600 million in annual net sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eAnsoff fit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eXtampza ER\u003c\/td\u003e\n\u003ctd\u003eAbuse-deterrent oxycodone ER\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNucynta ER\/IR\u003c\/td\u003e\n\u003ctd\u003eTapentadol line extension\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBelbuca\u003c\/td\u003e\n\u003ctd\u003eBuprenorphine buccal film\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSymproic\u003c\/td\u003e\n\u003ctd\u003eOIC therapy\u003c\/td\u003e\n\u003ctd\u003eAdjacent line extension\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIronshore acquisition, 2023\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical, Inc. bought Ironshore Therapeutics in 2023 for about $525 million, adding a non-pain specialty asset to its portfolio. That move was pure diversification in the Ansoff Matrix: it opened a new product family and a new market beyond its pain franchise. The deal also widened Collegium’s revenue base, with Ironshore’s specialty assets giving it more than one growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJornay PM methylphenidate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJornay PM, methylphenidate HCl for ADHD, is a different molecule from Collegium Pharmaceutical, Inc. pain brands, so it broadens the product mix into a new therapeutic category.\u003c\/p\u003e\n\u003cp\u003eIn Ansoff terms, this is diversification because the company is serving a new market with a non-core asset, not just extending its pain franchise.\u003c\/p\u003e\n\u003cp\u003eThat lowers dependence on opioid and non-opioid pain revenue and gives Collegium Pharmaceutical, Inc. a second growth path if ADHD adoption keeps building.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eADHD market entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJornay PM moved Collegium Pharmaceutical, Inc. into ADHD, a market outside its legacy pain franchise, so this is diversification, not market penetration. U.S. ADHD affects about 7 million children ages 3-17, giving Collegium a new patient pool and use case versus its opioid and non-opioid pain base. That shift also adds a second growth engine beyond pain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEvening-dosed CNS therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJornay PM adds evening-dosed CNS coverage to Collegium Pharmaceutical, Inc., using a delayed-release, extended-release stimulant that works differently from its opioid brands. That broadens the portfolio beyond pain and supports diversification into ADHD care, a market with millions of U.S. patients treated each year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDifferent dose timing and mechanism\u003c\/li\u003e\n\u003cli\u003eExpands beyond opioid revenue\u003c\/li\u003e\n\u003cli\u003eAdds non-pain specialty-therapy exposure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-pain revenue mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJornay PM broadens Collegium Pharmaceutical, Inc. beyond pain, so the company is no longer tied to a single therapy lane. That adds CNS specialty prescribing to a base that still includes pain medicines, which is the main diversification gain.\u003c\/p\u003e\n\u003cp\u003eThis matters because more than 1 revenue stream can soften mix risk if pain demand slows. The move also gives Collegium Pharmaceutical, Inc. a second specialist sales channel and deeper prescriber reach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLess pain-only exposure\u003c\/li\u003e\n\u003cli\u003eMore CNS revenue mix\u003c\/li\u003e\n\u003cli\u003eBroader prescriber base\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium Expands Beyond Pain With $525M ADHD Deal\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical, Inc. used diversification when it bought Ironshore Therapeutics in 2023 for about $525 million and added Jornay PM, a non-pain ADHD asset. That moved the company into a new therapy area beyond its core pain franchise. With about 7 million U.S. children ages 3-17 affected by ADHD, the deal gives Collegium Pharmaceutical, Inc. a second growth path.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDeal\u003c\/td\u003e\n\u003ctd\u003eIronshore Therapeutics, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice\u003c\/td\u003e\n\u003ctd\u003eAbout $525 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew market\u003c\/td\u003e\n\u003ctd\u003eADHD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. patient pool\u003c\/td\u003e\n\u003ctd\u003eAbout 7 million children\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234193973513,"sku":"coll-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/coll-ansoff-matrix.webp?v=1785715526","url":"https:\/\/dcfanalyst.com\/products\/coll-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}